162 related articles for article (PubMed ID: 33361605)
21. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
[TBL] [Abstract][Full Text] [Related]
22. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
Müller EG; Edwin TH; Stokke C; Navelsaker SS; Babovic A; Bogdanovic N; Knapskog AB; Revheim ME
PLoS One; 2019; 14(8):e0221365. PubMed ID: 31430334
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
[TBL] [Abstract][Full Text] [Related]
24. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
[TBL] [Abstract][Full Text] [Related]
26. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
27. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
28. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W
J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549
[TBL] [Abstract][Full Text] [Related]
29. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
30. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
31. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
32. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
[TBL] [Abstract][Full Text] [Related]
33. Applied multimodal diagnostics in a case of presenile dementia.
Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A
BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
[TBL] [Abstract][Full Text] [Related]
35. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
[TBL] [Abstract][Full Text] [Related]
36. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
37. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
[TBL] [Abstract][Full Text] [Related]
38. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
39. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
Wang ML; Wei XE; Yu MM; Li PY; Li WB;
Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
[TBL] [Abstract][Full Text] [Related]
40. Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Wang ZT; Li KY; Tan CC; Xu W; Shen XN; Cao XP; Wang P; Bi YL; Dong Q; Tan L; Yu JT
J Alzheimers Dis; 2021; 82(3):1045-1054. PubMed ID: 34151793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]